Efgartigimod: A novel antibody depletion therapy in myasthenia gravis

Affiliations

¹ From the Division of Neuromuscular Medicine, Department of Neurology (A.C.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Division of Neuromuscular Medicine, Department of Neurology (V.C.J.), Duke University Medical Center, Duke University, Durham, NC. aguidon@partners.org.
² From the Division of Neuromuscular Medicine, Department of Neurology (A.C.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Division of Neuromuscular Medicine, Department of Neurology (V.C.J.), Duke University Medical Center, Duke University, Durham, NC.

Editorial

Amanda C Guidon et al. Neurology. 2019.

. 2019 Jun 4;92(23):1079-1080.

doi: 10.1212/WNL.0000000000007605. Epub 2019 May 22.

¹ From the Division of Neuromuscular Medicine, Department of Neurology (A.C.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Division of Neuromuscular Medicine, Department of Neurology (V.C.J.), Duke University Medical Center, Duke University, Durham, NC. aguidon@partners.org.
² From the Division of Neuromuscular Medicine, Department of Neurology (A.C.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Division of Neuromuscular Medicine, Department of Neurology (V.C.J.), Duke University Medical Center, Duke University, Durham, NC.

No abstract available

Comment on

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.